Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Author Archives: Warren Woessner
Novelty and Obviousness In An Empirical Research Field – The Decision of the UK Court of Appeal in Dr Reddy’s Laboratories v Eli Lilly
From Paul Cole The Lilly patent for olanzapine has been litigated in many jurisdictions including the US, Canada, the Czech Republic, Finland, Levitra order online Romania, Slovakia, Slovenia, Spain, China and Hungary. In US Court of Appeals for the Federal … Continue reading
Posted in Non-U.S. Practice
Tagged biotechnology law, Dr Reddy's Laboratories, Eli Lilly, olanzapine, Paul Cole, Warren Woessner
Leave a comment
Neutrokine-α litigation – On a different record from that before the EPO Appeal Board, the UK Court of Appeal finds different facts with a different result
From Paul Cole of Lucas & Cole On February 9th the Court of Appeal ([2010] EWCA Civ 33; Jacob L.J.) held that Human Genome Sciences Patent EP-B-093 cheap cialis online 9804 for Neutrokine-α did not meet the industrial applicability requirement … Continue reading
Posted in Utility/How-To-Use
Tagged biotechnology patent law, EPO, neutrokine, Paul Cole, Warren Woessner
Leave a comment
USPTO Request for Comments on Enhancement in the Quality of Patents
In the December 9, 2009 issue of the Fed. Reg., the PTO requested public comments on a wide range of patent preparation and prosecution topics, from “Finding the Best Prior Art” to issuing and responding to first office actions and … Continue reading
BIO Joins Stakeholders in Expressing Concerns with Efforts to Restrict Gene Patenting
Today, the Secretary’s Advisory Committee on Genetics Health and Society (SACGHS), approved, with on dissent, a draft report which recommends legislative changes to the patent laws in regards to gene patents and recommends restrictions on licensing of federally funded research. … Continue reading